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Background: Reporting of outcomes after transcatheter aortic valve implantation
(TAVI) has been variable. To allow comparison of these multiple non-randomized trials,
the Valve Academic Research Consortium (VARC) recently introduced standardized
endpoint definitions. We sought to re-evaluate our single-center experience with TAVI
following the VARC definitions.
Methods: From 03/2008 to 06/2011, 285 patients underwent TAVI with Edwards
Sapien (ES; Edwards Lifesciences, Irvine, CA) or CoreValve (CV; Medtronic,
Minneapolis, MN) devices at our institution. Data were gathered prospectively at
baseline, discharge, 30 days and 1 year after TAVI. Retrospective analysis was done
according to endpoints recently defined by the VARC.
Results: TAVI was performed via the transapical (TA) approach using the ES in 164
(57.5%) and transfemoral (TF) access in 121 (42.5%; ES: 65.3%, CV: 34.7%) patients.
Mean age was 79.9±9.1 years and the TA group showed a higher risk profile with a
log EuroSCORE of 25.6±12.8% (TA) vs. 20.4±12.4% (TF; p=0.002). All-cause
mortality was 11.1% (TF) vs. 11.2% (TA) at 30 days and 28.1% (TF) vs. 29.1% (TA)
at 1 year. Device success was achieved in 86.8% (TF) and 85.4% (TA) of TAVI
procedures and 30-day mortality was 8.1% and 10.1% in these patients. The combined
30-day safety endpoint was reached in 15.7% of TF and 20.1% of TA cases.
Periprocedural myocardial infarction occurred in 0.8% (TF) and 0.6% (TA), major
stroke in 5.0% (TF) and 5.5% (TA), and severe acute kidney injury in 3.3% (TF) and
4.3% (TA). Access site complications were observed in 10.7% (TF) and 3.7% (TA).
Conduction disorders required permanent pacemaker implantation in 14.9% (TF; ES:
7.6%, CV: 28.6%) and 13.4% (TA) of patients. NYHA class improved by 1.1±0.7 (TF)
and 0.9±0.6 (TA) at 30-day and 0.9±0.6 (TF) and 1.1±0.9 (TA) at 1-year follow-up.
Conclusion: According to standardized endpoint definitions published by the VARC,
TAVI with TA and TF approaches can be performed with comparable survival.
Nevertheless, the higher risk profile in TA patients seems to find its expression in a
higher combined 30-day safety endpoint although this was not reflected in delayed
clinical improvement. Device success was not a predictor of survival in this patient
series.
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Background: Older age is a predictor of early and late mortality following surgical
aortic replacement. Patients undergoing transcatheter aortic valve implantation (TAVI)
are elderly and associated with multiple comorbidities. We aim to investigate whether
differences exist in clinical presentation and outcomes according to age in patients
undergoing TAVI.
Methods: From June 2007 to June 2010 consecutive TAVI patients were prospectively
entered into a dedicated database. Patients were subdivided into age tertiles (A1 to A3)
and these subgroups were subsequently examined for any differences in baseline
characteristics, and 30-day and 6-month mortality. Kaplan Meier curves were used to
estimate survival in all groups.
Results: A total of 501 patients underwent TAVI (n=342 CoreValve and n=159
Edwards SAPIEN). The age tertiles were identified as < 78 years (A1, n=164 patients),
79 to 83 years (A2, n=173 patients) and older than 84 years (A3, n=164 patients). As
compared to A1 patients, A3 patients had higher logistic EuroSCORES (23.4±12.7 vs.
15.7±11.0%, p<0.001), higher STS scores (7.6±4.2 vs. 4.2±3.4%, p<0.001), higher
baseline creatinine levels (1.3±0.5 vs. 1.2±0.73 mg/dl, p=0.03) and more coronary
artery disease (64 vs. 47.6%, p=0.008). The 30-day mortality was 4-fold higher in A3
than in A1 (11.4 vs. 3.6%, p=0.03) whereas there was no significant difference in
mortality observed between A3 and A1 at 6-month follow-up (19 to 15%, p=0.45).
Conclusion: In this TAVI cohort, the 30-day mortality was 4-fold higher in those
patients older than 84 years than in those less than 78 years; these differences were no
longer appreciated at 6-month follow-up.
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Background: Balloon aortic valvuloplasty (BAV) is a therapeutic option for patients
with severe aortic stenosis (AS). Clinical outcomes with BAV are limited by restenosis
and high mortality rates as compared to surgical aortic valve replacement (AVR). AVR
is the recommended therapy for patients with severe AS. BAV as a bridge to AVR for
high-surgical risk AS patients has been reported. Transcatheter aortic valve
implantation (TAVI) has equal safety and efficacy outcomes compared to AVR.
Currently, there is a paucity of information describing the utilization of BAV as a bridge
to definitive therapy in the modern era of AVR and TAVI.
Methods: We compared the safety and clinical outcomes associated with BAV alone,
to BAV as a bridge to AVR or to TAVI among a high-surgical risk cohort of patients
with severe AS.
Results: The medical records of patients who received a BAV procedure for severe
AS were analyzed and included in the study (80 patients). Baseline STS scores were
higher in the TAVI cohort; other baseline demographics were similar across study
cohorts (Table 1). Ten patients were bridged to AVR and fifteen patients were
successfully bridged to TAVI. Clinical outcomes of all cause death, cardiovascular
death, death 30 days after BAV and rehospitalization for heart failure were compared
among the 3 study cohorts (Table 1). There was a significant higher rate of all cause
death, cardiovascular death and rehospitalization for heart failure among the BAV-
alone cohort compared to the BAV-bridge cohorts (Table 1). Complications rates were
low and occurred only in the BAV-alone cohort (Table 1).
Conclusion: BAV is an effective and safe therapeutic option as a bridge to AVR or
TAVI. BAV should be considered prior to AVR or TAVI in high-surgical risk patients
with severe AS.
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Background: An optimal fluoroscopic working view projection (OP) with all three
aortic sinuses aligned is crucial during trans-catheter aortic valve implantation (TAVI).
The aim of this study was to identify simple reference projection angles, which would
act as a starting point for the operator to help determine OP in patients.
Methods: Procedural outcome data was collected prospectively from 50 patients
undergoing TAVI. Optimal angiographic deployment angles were achieved for all
patients by starting in an anteroposterior caudal 15 degrees projection and then
adjusting according to the initial image, with multiple small volume contrast injections
undertaken to determine when all 3 aortic cusps were aligned (OP).
Results: OP angles for the 50 cases were plotted.(Figure 1)Regression analysis enabled
a regression line to be calculated. The equation for the regression line was defined as
caudal intercept -14.8±1.9 (SEcoefficient), p<0.0001, slope of regression line +
0.453±0.1 (SEcoefficient), p<0.002).
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